Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators
- 17 June 2008
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 22 (10), 3595-3606
- https://doi.org/10.1096/fj.08-112201
Abstract
Atherosclerosis is now recognized as an inflammatory disease involving the vascular wall. Recent results indicate that acute inflammation does not simply passively resolve as previously assumed but is actively terminated by a homeostatic process that is governed by specific lipid-derived mediators initiated by lipoxygenases. Experiments with animals and humans support a proinflammatory role for the 5-lipoxygenase system. In contrast, results from animal experiments show a range of responses with the 12/15-lipoxygenase pathways in atherosclerosis. To date, the only two clinical epidemiology human studies both support an antiatherogenic role for 12/15-lipoxygenase downstream actions. We tested the hypothesis that atherosclerosis results from a failure in the resolution of local inflammation by analyzing apolipoprotein E-deficient mice with 1) global leukocyte 12/15-lipoxygenase deficiency, 2) normal enzyme expression, or 3) macrophage-specific 12/15-lipoxygenase overexpression. Results from these indicate that 12/15-lipoxygenase expression protects mice against atherosclerosis via its role in the local biosynthesis of lipid mediators, including lipoxin A(4), resolvin D1, and protectin D1. These mediators exert potent agonist actions on macrophages and vascular endothelial cells that can control the magnitude of the local inflammatory response. Taken together, these findings suggest that a failure of local endogenous resolution mechanisms may underlie the unremitting inflammation that fuels atherosclerosis.Keywords
Funding Information
- American Heart Association (0465093Y, 0730172N)
- National Institutes of Health (P50 DE016191, HL‐51586)
This publication has 52 references indexed in Scilit:
- A near null variant of 12/15-LOX encoded by a novel SNP in ALOX15 and the risk of coronary artery diseaseAtherosclerosis, 2008
- Anti-Inflammatory Actions of Neuroprotectin D1/Protectin D1 and Its Natural Stereoisomers: Assignments of Dihydroxy-Containing DocosatrienesThe Journal of Immunology, 2006
- Resolution of inflammation: the beginning programs the endNature Immunology, 2005
- A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer diseaseJCI Insight, 2005
- The Absence of Platelet-Derived Growth Factor-B in Circulating Cells Promotes Immune and Inflammatory Responses in Atherosclerosis-Prone ApoE−/− MiceThe American Journal of Pathology, 2005
- Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic miceJCI Insight, 2005
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseThe New England Journal of Medicine, 2005
- A Role for the Mouse 12/15-Lipoxygenase Pathway in Promoting Epithelial Wound Healing and Host DefenseJournal of Biological Chemistry, 2005
- Association between the Gene Encoding 5-Lipoxygenase–Activating Protein and Stroke Replicated in a Scottish PopulationAmerican Journal of Human Genetics, 2005
- Lipoxin (LX)A4 and Aspirin-triggered 15-epi-LXA4 Inhibit Tumor Necrosis Factor 1α–initiated Neutrophil Responses and Trafficking: Regulators of a Cytokine–Chemokine AxisThe Journal of Experimental Medicine, 1999